

# Tuberculosis profile: Malaysia

Population 2021: 34 million

## Estimates of TB burden\*, 2021

|                           | Number                 | (Rate per 100 000 population) |
|---------------------------|------------------------|-------------------------------|
| Total TB incidence        | 33 000 (28 000-38 000) | 97 (83-112)                   |
| HIV-positive TB incidence | 1 300 (1 100-1 500)    | 3.9 (3.3-4.6)                 |
| MDR/RR-TB incidence**     | 540 (430-660)          | 1.6 (1.3-2)                   |
| HIV-negative TB mortality | 2 000 (1 300-2 900)    | 6 (4-8.5)                     |
| HIV-positive TB mortality | 530 (350-750)          | 1.6 (1-2.2)                   |

## Estimated proportion of TB cases with MDR/RR-TB\*, 2021

|                          |                 |
|--------------------------|-----------------|
| New cases                | 0.94% (0.8-1.1) |
| Previously treated cases | 19% (14-24)     |

## Universal health coverage and social protection\*

|  |             |
|--|-------------|
| TB treatment coverage (notified/estimated incidence), 2021             | 65% (56-76) |
| TB patients facing catastrophic total costs                            |             |
| TB case fatality ratio (estimated mortality/estimated incidence), 2021 | 8% (5-11)   |

## TB case notifications, 2021

|  |        |
|--|--------|
| Total new and relapse                                  | 21 186 |
| - % tested with rapid diagnostics at time of diagnosis |        |
| - % with known HIV status                              | 94%    |
| - % pulmonary  | 83%    |
| - % bacteriologically confirmed <sup>^</sup>           | 74%    |
| - % children aged 0-14 years                           | 3%     |
| - % women (aged ≥15 years)                             | 35%    |
| - % men (aged ≥15 years)                               | 62%    |
| Total cases notified                                   | 21 727 |

## TB/HIV care in new and relapse TB patients, 2021

|   | Number | (%)  |
|---|--------|------|
| Patients with known HIV status who are HIV-positive | 808    | 4.1% |
| - on antiretroviral therapy                         | 258    | 32%  |

## Drug-resistant TB care\*\*, 2021

|  |     |
|--|-----|
| % of bacteriologically confirmed TB cases tested for rifampicin resistance - New cases <sup>^</sup>                | 84% |
| % of bacteriologically confirmed TB cases tested for rifampicin resistance - Previously treated cases <sup>^</sup> | 77% |
| Laboratory-confirmed cases - MDR/RR-TB <sup>^^</sup>   | 199 |
| Patients started on treatment - MDR/RR-TB <sup>^^^</sup>   | 170 |
| Laboratory-confirmed cases - pre-XDR-TB or XDR-TB <sup>^^</sup>  | 3   |
| Patients started on treatment - pre-XDR-TB or XDR-TB <sup>^^^</sup>  | 2   |
| MDR/RR-TB cases tested for resistance to any fluoroquinolone   | 98  |

## Treatment success rate and cohort size

|  | Success | Cohort |
|--|---------|--------|
| New and relapse cases registered in 2020                         | 78%     | 22 973 |
| Previously treated cases, excluding relapse, registered in 2020  | 45%     | 671    |
| HIV-positive TB cases registered in 2020                         | 57%     | 1 075  |
| MDR/RR-TB cases started on second-line treatment in 2019         | 55%     | 169    |
| Pre-XDR-TB/XDR-TB cases started on second-line treatment in 2019 | 33%     | 3      |


## TB preventive treatment, 2021

|   |               |
|---|---------------|
| % of HIV-positive people (newly enrolled in care) on preventive treatment   | 19%           |
| % of children (aged < 5 years) household contacts of bacteriologically-confirmed TB cases on preventive treatment | 100% (97-100) |


## Funding for TB

**Error:** An error has occurred. Check your logs or contact the app author for clarification.


## Incidence, New and relapse TB cases notified, HIV-positive TB incidence (Rate per 100 000 population per year)




## HIV-negative TB mortality (Rate per 100 000 population per year)




## Incidence, Notified cases by age group and sex, 2021 (Number)



## Cases attributable to five risk factors, 2021 (Number)



## Funding for TB (US\$ millions)



\* Estimates of TB burden are produced by WHO in consultation with countries. Ranges represent uncertainty intervals.  
\*\* RR is TB resistant to rifampicin (R), MDR is TB resistant to R + isoniazid; pre-XDR is TB resistant to R + any fluoroquinolone  
^ Calculated for pulmonary cases only  
^^ Includes cases with unknown previous TB treatment history  
^^^ Includes patients diagnosed before 2021 and patients who were not laboratory-confirmed

---

Generated 2022-11-28 by the World Health Organization (<https://www.who.int/teams/global-tuberculosis-programme/data>)